Cargando…

BRAF(V600E) mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population

BACKGROUND: Melanocytic neoplasms range from banal nevi to malignant melanomas. The genetic background has been extensively studied in the Caucasian population. BRAF mutations were reported among the early driver mutations in nevogenesis. Nevertheless, the pathogenesis in the Egyptian population has...

Descripción completa

Detalles Bibliográficos
Autores principales: Yakout, Nada M., Abdallah, Dina M., Abdelmonsif, Doaa A., Kholosy, Hassan Mahmoud, Talaat, Iman M., Elsakka, Omayma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896695/
https://www.ncbi.nlm.nih.gov/pubmed/36737739
http://dx.doi.org/10.1186/s12935-023-02858-1
_version_ 1784882105050726400
author Yakout, Nada M.
Abdallah, Dina M.
Abdelmonsif, Doaa A.
Kholosy, Hassan Mahmoud
Talaat, Iman M.
Elsakka, Omayma
author_facet Yakout, Nada M.
Abdallah, Dina M.
Abdelmonsif, Doaa A.
Kholosy, Hassan Mahmoud
Talaat, Iman M.
Elsakka, Omayma
author_sort Yakout, Nada M.
collection PubMed
description BACKGROUND: Melanocytic neoplasms range from banal nevi to malignant melanomas. The genetic background has been extensively studied in the Caucasian population. BRAF mutations were reported among the early driver mutations in nevogenesis. Nevertheless, the pathogenesis in the Egyptian population has not been elucidated. AIM AND METHODS: The present study was carried out to assess the sensitivity and specificity of immunohistochemistry (IHC) using the RM-08 clone in reference to allele-specific real-time PCR (CAST-PCR) for the detection of the BRAF (V600E) mutation in 50 formalin-fixed paraffin-embedded blocks of melanocytic neoplasms with prior bleaching using hydrogen peroxide in Tris-HCL and Bovine Serum Albumin respectively. RESULTS: IHC staining was interpreted using staining reaction (positive versus negative) and staining pattern (negative and heterogeneous versus homogenous). Using the staining pattern, the specificity increased from 73.3 to 88.2%, the negative predictive value increased from 73.3 to 100%, the diagnostic accuracy increased from 71.4 to 90.48% and the overall accuracy increased from 69.9 to 77.3%. The sensitivity and positive predictive value remained unchanged. The K-agreement coefficient increased from 0.364 (fair agreement) to 0.741 (good agreement) and was statistically significant (p = 0.00). Next-generation sequencing was performed in 11 cases, 8 cases with IHC-positive and BRAF (wild type) in addition to 3 cases that failed PCR analysis and revealed no BRAF (V600E). No statistically significant difference was found in the clinicopathological parameters between BRAF (V600E) and BRAF (wild−type) melanomas. CONCLUSIONS: These findings suggest that IHC staining homogeneity may be more accurate in predicting BRAF (V600E) mutational status. However, IHC cannot replace molecular methods.
format Online
Article
Text
id pubmed-9896695
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98966952023-02-04 BRAF(V600E) mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population Yakout, Nada M. Abdallah, Dina M. Abdelmonsif, Doaa A. Kholosy, Hassan Mahmoud Talaat, Iman M. Elsakka, Omayma Cancer Cell Int Research BACKGROUND: Melanocytic neoplasms range from banal nevi to malignant melanomas. The genetic background has been extensively studied in the Caucasian population. BRAF mutations were reported among the early driver mutations in nevogenesis. Nevertheless, the pathogenesis in the Egyptian population has not been elucidated. AIM AND METHODS: The present study was carried out to assess the sensitivity and specificity of immunohistochemistry (IHC) using the RM-08 clone in reference to allele-specific real-time PCR (CAST-PCR) for the detection of the BRAF (V600E) mutation in 50 formalin-fixed paraffin-embedded blocks of melanocytic neoplasms with prior bleaching using hydrogen peroxide in Tris-HCL and Bovine Serum Albumin respectively. RESULTS: IHC staining was interpreted using staining reaction (positive versus negative) and staining pattern (negative and heterogeneous versus homogenous). Using the staining pattern, the specificity increased from 73.3 to 88.2%, the negative predictive value increased from 73.3 to 100%, the diagnostic accuracy increased from 71.4 to 90.48% and the overall accuracy increased from 69.9 to 77.3%. The sensitivity and positive predictive value remained unchanged. The K-agreement coefficient increased from 0.364 (fair agreement) to 0.741 (good agreement) and was statistically significant (p = 0.00). Next-generation sequencing was performed in 11 cases, 8 cases with IHC-positive and BRAF (wild type) in addition to 3 cases that failed PCR analysis and revealed no BRAF (V600E). No statistically significant difference was found in the clinicopathological parameters between BRAF (V600E) and BRAF (wild−type) melanomas. CONCLUSIONS: These findings suggest that IHC staining homogeneity may be more accurate in predicting BRAF (V600E) mutational status. However, IHC cannot replace molecular methods. BioMed Central 2023-02-03 /pmc/articles/PMC9896695/ /pubmed/36737739 http://dx.doi.org/10.1186/s12935-023-02858-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yakout, Nada M.
Abdallah, Dina M.
Abdelmonsif, Doaa A.
Kholosy, Hassan Mahmoud
Talaat, Iman M.
Elsakka, Omayma
BRAF(V600E) mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population
title BRAF(V600E) mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population
title_full BRAF(V600E) mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population
title_fullStr BRAF(V600E) mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population
title_full_unstemmed BRAF(V600E) mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population
title_short BRAF(V600E) mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population
title_sort braf(v600e) mutational status assessment in cutaneous melanocytic neoplasms in a group of the egyptian population
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896695/
https://www.ncbi.nlm.nih.gov/pubmed/36737739
http://dx.doi.org/10.1186/s12935-023-02858-1
work_keys_str_mv AT yakoutnadam brafv600emutationalstatusassessmentincutaneousmelanocyticneoplasmsinagroupoftheegyptianpopulation
AT abdallahdinam brafv600emutationalstatusassessmentincutaneousmelanocyticneoplasmsinagroupoftheegyptianpopulation
AT abdelmonsifdoaaa brafv600emutationalstatusassessmentincutaneousmelanocyticneoplasmsinagroupoftheegyptianpopulation
AT kholosyhassanmahmoud brafv600emutationalstatusassessmentincutaneousmelanocyticneoplasmsinagroupoftheegyptianpopulation
AT talaatimanm brafv600emutationalstatusassessmentincutaneousmelanocyticneoplasmsinagroupoftheegyptianpopulation
AT elsakkaomayma brafv600emutationalstatusassessmentincutaneousmelanocyticneoplasmsinagroupoftheegyptianpopulation